Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supha PharmachemBOM:539561 +3.23%54 Interest Coverage is 39.37 as of Sep. 2025, which is 27% above its 10-year median of 30.95. GuruFocus rates BOM:539561 with a GF Score™ of 54/100 and a GF Value™ of ₹1.52 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 687 Drug Manufacturers companies, Supha Pharmachem ranks worse than 91.85% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Supha Pharmachem's
Operating Income
for the
three
months ended in Sep. 2025 was ₹74 Mil. Supha Pharmachem's Interest Expense for the
three
months ended in Sep. 2025 was ₹-2 Mil.
Supha Pharmachem's interest coverage for the quarter that ended in Sep. 2025 was 39.37.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Supha Pharmachem Ltd interest coverage is 1.13, which is low.
The historical rank and industry rank for Supha Pharmachem's Interest Coverage or its related term are showing as below:
BOM:539561'
s Interest Coverage Range Over the Past 10 Years
Min: 0.16 Med: 30.95 Max: 119.53
Current: 1.13
BOM:539561's Interest Coverage is ranked worse than 91.85% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:539561: 1.13
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Supha Pharmachem Interest Coverage Related Terms
Supha Pharmachem Interest Coverage Historical Data
* Premium members only.
The historical data trend for Supha Pharmachem's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:539561 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supha Pharmachem Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Supha Pharmachem's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supha Pharmachem (BOM:539561) has a Interest Coverage of 39.37 as of Sep. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Supha Pharmachem and its competitors. This is 27% above median its historical median of 30.95. Over the past decade, Supha Pharmachem's Interest Coverage has ranged from 0.16 to 119.53. According to the industry distribution chart, Supha Pharmachem ranks #631 out of 687 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is Supha Pharmachem's Interest Coverage too high?
Supha Pharmachem's current Interest Coverage of 39.37 is 27% above median its 10-year median of 30.95. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 119.53. The Drug Manufacturers industry median Interest Coverage is 12.75. Supha Pharmachem's value of 39.37 is 208.8% above this industry median. Based on the distribution chart, Supha Pharmachem ranks #631 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supha Pharmachem has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Supha Pharmachem ranks #631 out of 687 companies for Interest Coverage. This places Supha Pharmachem in the lower half of its industry. The industry median Interest Coverage is 12.75. Supha Pharmachem's value of 39.37 is 208.8% above this benchmark. Historically, Supha Pharmachem's own Interest Coverage has ranged from 0.16 to 119.53 over the past decade. While the company's 10-year median is 30.95 vs. the industry median of 12.75, Supha Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supha Pharmachem's current Interest Coverage of 39.37 is 208.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Supha Pharmachem and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supha Pharmachem's current Interest Coverage is 39.37, which is 27% above median its own 10-year median of 30.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.52, compared to a current price of ₹0.32 — trading 78.9% below its estimated fair value. The current Interest Coverage is 39.37, which is 27% above median its 10-year median of 30.95 and 208.8% above the Drug Manufacturers industry median of 12.75. Supha Pharmachem's overall GF Score™ is 54/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current Interest Coverage is 39.37 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supha Pharmachem (BOM:539561) Overvalued in 2026?
Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued.
The current stock price of ₹0.32 is trading 78.9% below its estimated GF Value™ of ₹1.52.
GuruFocus considers Supha Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:539561:
Interest Coverage: 39.37 (27% above median its 10-year median of 30.95)
GF Value™: ₹1.52 vs. price of ₹0.32 (78.9% below fair value)
Industry Position: 208.8% above the Drug Manufacturers median (#631 of 687)
No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
54GF Score
Get the complete analysis for BOM:539561
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539561 has been successfully added to your 
